Laura Vellucci

Deucravacitinib, a selective tyrosine kinase 2 inhibitor, for the treatment of moderate-to-severe plaque psoriasis

Lorenzo Marcelli, L. Bianchi, M. Talamonti, 2023, Expert opinion on pharmacotherapy.

Guselkumab for treatment of moderate-to-severe plaque psoriasis: real-life effectiveness and drug-survival for up to 148 weeks

L. Tofani, L. Bianchi, M. Talamonti, 2023, Expert opinion on biological therapy.

Cemiplimab and ruxolitinib in concomitant cutaneous squamous cell carcinoma and myelofibrosis

L. Tofani, C. Di Raimondo, L. Bianchi, 2022, Dermatologic therapy.